Evidence map›Paper›PMID 35492872›Full record

ReviewClinical and translational radiation oncology2022

Irradiation of localized prostate cancer in the elderly: A systematic literature review.

Delphine Marotte, Marie-Eve Chand-Fouche, Rabia Boulahssass, Jean-Michel Hannoun-Levi

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and translational radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Delphine MarotteDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Marie-Eve Chand-FoucheDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Rabia BoulahssassGeriatric Coordination Unit for Geriatric Oncology (UCOG) PACA Est, CHU de NICE, University of Cote d'Azur, Oncoage Nice, France.
Jean-Michel Hannoun-LeviDepartment of Radiation Oncology, Antoine Lacassagne Cancer Center, University of Côte d'Azur, 33 avenue Valombrose, 06189 Nice Cedex 2, Nice, France.
Centre Antoine Lacassagne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To analyze the literature that addresses radiation therapy for intermediate and high-risk prostate cancer (PC) in the elderly. Patients and methods: A PubMed literature search was conducted including articles from 01/01/2000 to 30/06/21, with the following keywords: PC, radiotherapy/brachytherapy and elderly. The analysis mainly focused on the issue of under-treatment in the elderly and the benefit/risk balance of irradiation. Results: Of the 176 references analyzed, 24 matched the selection criteria. The definition of "elderly patient" varied from 70 to 80 years. The analysis was impacted by the inhomogeneous primary end points used in each cohort. Age was often an obstacle to radical treatment, with a subsequent risk of under-treatment, particularly in patients with a poorer prognosis. However, comparable elderly oncological outcomes were compared to younger patients, both with external beam radiotherapy alone or combined with brachytherapy boost. Late toxicity rates are low and most often comparable to younger populations. However, a urinary over- toxicity was observed in the super-elderly (>80 years) after brachytherapy boost. The use of ADT should be considered in light of comorbidities, and may even be deleterious in some patients. Conclusion: Due to the increase in life expectancy, the management of PC in the elderly is a challenge for patients, clinicians and health insurance payers. Except for unfit men, elderly patients remain candidates for optimal curative treatment (i.e. regardless of age) after oncogeriatric assessment. More solid data from prospective trials conducted specially in this population will provide better guidance in our daily clinical practice.

Indexed as

3DCT, 3D conformal radiotherapyACE-27, Adult Comorbidity Evaluation 27AD, Alzheimer’s diseaseADT, androgen deprivation therapyAndrogen deprivation therapyASCO, American Society of Clinical OncologybNED, Biological non-evidence of diseaseBrachytherapyBRFS, biochemical relapse-free survivalBT, brachytherapyCCI, Charlson comorbidity indexEBRT, External beam radiation therapyElderlyG, gradeGI, Gastro-intestinalGI, Genito-urinaryHDR, high dose-rateIGRT, Image Guided Radiation TherapyIMRT, intensity modulated radiation therapyLDR, low dose-rateLE, life expectancyMA, median ageMFU, median follow-upNCCN, National Comprehensive Cancer NetworkOS, overall survivalPC, prostate cancerPCSM, prostate cancer specific mortalityPCSS, Prostate cancer specific survivalProstate cancerQoL, quality of lifeRadiation therapySBRT, stereotactic body radiation therapySEER, Surveillance, Epidemiology, and End ResultsSIOG, International Society of Geriatric Oncology

Identifiers

PMID35492872
PMCPMC9046879
OpenAlexW4224302826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.